Trial intelligence / Profile preview

Gemcitabine and Cisplatin in Advanced Penile Squamous Cell Carcinoma

NCT00210041Phase 2Completed

Sponsor
Institut Claudius Regaud
Start
Feb 2004
Primary completion
Dec 2011
Modality
Nanoparticles, Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of gemcitabine and Cisplatin micelle injection (HA132) in penile squamous cell carcinoma (PSCC), sponsored by Institut Claudius Regaud. Primary endpoint: Objective Response Rate. Started Feb 2004; status: completed.

02

Drugs

gemcitabineCisplatin micelle injection (HA132)
03

Conditions

penile squamous cell carcinoma (PSCC)

Beyond the preview

Go deeper on NCT00210041.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00210041.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call